News ArticleVodafone Idea schedules board meeting on 12 November for Q2 and H1 2026 financial results approval
Trading window remains closed from 1 October to 14 November 2026 as per regulatory norms
Vodafone Idea Limited announced a board meeting for 12 November 2026 to consider and approve its unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2026. The trading window is closed from 1 October to 14 November 2026 in accordance with regulatory requirements.
Vodafone Idea Limited
General / Other
Vodafone Idea Limited will hold its Board of Directors meeting on 12 November 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026.
The meeting is scheduled under Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The company has previously informed that the trading window for dealing in its securities has been closed from 1 October 2026 and will remain closed until 14 November 2026, inclusive of both days, to comply with insider trading regulations.
The financial results to be considered include both standalone and consolidated figures for the specified periods.
Highlights
- Board meeting date: 12 November 2026
- Financial results for Q2 and H1 ended 30 September 2026 to be reviewed and approved
- Trading window closed from 1 October to 14 November 2026 under SEBI regulations
- Meeting scheduled pursuant to SEBI Listing Regulations, Regulation 29
Key Data Snapshot
What happened
- Vodafone Idea Limited announced a board meeting to be held on 12 November 2026.
- The meeting agenda includes consideration and approval of unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2026.
Key details
- The meeting is scheduled under the SEBI Listing Regulations, 2015, Regulation 29.
- Trading window for dealing in securities of the company has been closed from 1 October 2026 and will remain closed until 14 November 2026, covering the financial results announcement period.
Regulatory and governance context
- Announcement complies with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
- Trading window closure is in accordance with insider trading norms under SEBI regulations.
Highlights
- Board meeting date: 12 November 2026
- Financial results for Q2 and H1 ended 30 September 2026 to be reviewed and approved
- Trading window closed from 1 October to 14 November 2026 under SEBI regulations
- Meeting scheduled pursuant to SEBI Listing Regulations, Regulation 29
Disclosures
- SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, Regulation 29
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
